Skip to main content
. 2005 Dec 1;173(5):519–526. doi: 10.1164/rccm.200509-1519OC

Figure 4.

Figure 4.

Change from baseline in a.m. PEF in subjects from the SLIC trial who were treated with salmeterol and constant triamcinolone dose throughout entire trial period, in B16Arg/Arg and B16Gly/Gly subjects; p values are for comparisons between genotype groups at the end of the randomized treatment period (Week 18). Each line represents linear segmental depictions of mean data.

HHS Vulnerability Disclosure